Monte Rosa Therapeutics GLUE
NASDAQ GLUE
$11.99 +0.25 (+2.13%)
As of: Sep 30, 2026 · 3:39 PM EDT

Monte Rosa Therapeutics (GLUE) Receivables (2024)

Updated

Monte Rosa Therapeutics (GLUE) recorded Receivables of $9.84 million in Q2 2024.

Analysis

Monte Rosa Therapeutics (GLUE) Receivables (2024) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Receivables (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn 19.05 Bn
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn 13.82 Bn
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn 12.56 Bn
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn 9.64 Bn
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn 15.68 Bn
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn 10.23 Bn
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn 5.06 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 12.49 Bn
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn 2.13 Bn
10 Monte Rosa Therapeutics 1.00 Bn 412.37 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2024 9.84 Mn
API Access

Monte Rosa Therapeutics Receivables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables&ticker=GLUE&period=max&api_key=YOUR_API_KEY